Risks
4 risks
Risk Intelligence
Sustained API price weakness
View Risks →Akums Drugs & Pharmaceuticals Ltd — Q4 FY26
Akums Drugs reported a strong Q4 FY26 with consolidated revenue of ₹1,158 crore (+9.7% YoY) and adjusted EBITDA of ₹152 crore (+61.6% YoY), driven by robust CDMO volume growth of over 25% in H2.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Akums Drugs reported a strong Q4 FY26 with consolidated revenue of ₹1,158 crore (+9.7% YoY) and adjusted EBITDA of ₹152 crore (+61.6% YoY), driven by robust CDMO volume growth of over 25% in H2. The CDMO segment posted revenue of ₹952 crore (+13.4% YoY) with EBITDA margins expanding to 14.4% on operating leverage and improved product mix. Domestic branded formulations grew modestly but margins improved, while trade generics turned EBITDA positive. API business remained a drag with losses of ₹12 crore in Q4. Management guided for continued double-digit CDMO volume growth in H1 FY27, with the Zambia contract (USD 25 million annually) expected to commence by Q2 FY27 and the European CDMO contract (€35 million annual run-rate) from FY28. Capex for FY27 is planned at ₹300 crore. Key risk: sustained API price weakness or further erosion could delay the turnaround in the API segment.
अकुम्स ड्रग्स ने वित्त वर्ष 2026 की चौथी तिमाही में मजबूत प्रदर्शन किया। कंपनी की कुल आय ₹1,158 करोड़ रही, जो पिछले साल से 9.7% ज्यादा है। समायोजित EBITDA (कमाई) ₹152 करोड़ रही, जो 61.6% बढ़ी। इसकी वजह CDMO (दूसरी कंपनियों के लिए दवा बनाने का काम) में दूसरी छमाही में 25% से ज्यादा वृद्धि थी। CDMO से ₹952 करोड़ की आय हुई और इसका मुनाफा 14.4% तक पहुंच गया। घरेलू ब्रांडेड दवाओं की बिक्री धीमी रही, लेकिन मुनाफा बढ़ा। ट्रेड जेनेरिक (सस्ती दवाएं) ने मुनाफा देना शुरू कर दिया। API (दवा बनाने का कच्चा माल) कारोबार में ₹12 करोड़ का नुकसान हुआ। कंपनी को उम्मीद है कि अगले साल की पहली छमाही में CDMO में दो अंकों की वृद्धि होगी। जाम्बिया और यूरोप के नए अनुबंध जल्द शुरू होंगे। अगले साल ₹300 करोड़ का निवेश योजना है। मुख्य जोखिम: API की कीमतें कमजोर रहीं तो इस कारोबार को उबरने में देरी हो सकती है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
CDMO Volume Growth (H2 FY26)
>25%
+25pp YoY
Volume growth in CDMO exceeded 25% in H2 FY26, driven by existing customers and wallet share gains.
CDMO EBITDA Margin (Q4 FY26)
14.4%
+550bps YoY
CDMO EBITDA margin expanded to 14.4% in Q4 from 8.9% a year ago, aided by operating leverage.
Zambia Contract Value
$25M
New
Annual supply contract to Zambia worth USD 25 million, expected to start in Q2 FY27.
European CDMO Contract Annual Run-rate
€35M
New
European CDMO contract has a fixed annual run-rate of €35 million for 6 years starting FY28.
What Changed vs Last Quarter
NEW
Zambia contract to commence by Q2 FY27
Commercial supplies of approximately USD 25 million from Indian facilities to Zambia expected to start by end of Q2 FY27.
NEW
Capex target of ₹300 crore for FY27
The company plans to spend around ₹300 crore on capex in FY27, primarily for oral solid capacity expansion.
NEW
API losses to reduce sharply in FY27
Management expects API segment losses to come down significantly in FY27, though full-year EBITDA may still be negative.
UPDATED
CDMO double-digit volume growth in H1 FY27
Management expects continued double-digit volume growth in CDMO for the first half of FY27, with visibility of 45-60 days.
DROPPED
EU CDMO contract annual run-rate of €35 million
The EU CDMO contract is expected to generate annual revenue of €35 million once commercial supplies begin, with supplies starting in FY28.
DROPPED
Zambia project $25 million supplies from H1 FY27
Commercial supplies of $25 million from Indian plants to Zambia expected in H1 FY27, with similar amount in FY28.
DROPPED
Capex to remain in line with historical trend
Capital expenditure for FY27 is expected to be consistent with past levels, focusing on maintenance and modernization.
NEW RISK
Sustained API price weakness
API prices remain lower than last year despite recent uptick; further decline could delay turnaround and keep losses elevated.
NEW RISK
Execution risk in Zambia and European contracts
Delays in regulatory approvals or tech transfer could push back revenue recognition from these large contracts.
NEW RISK
GLP-1 market entry uncertainty
Management was evasive on GLP-1 strategy, citing pricing volatility; missing this opportunity could limit future growth.
NEW RISK
Working capital increase
Working capital days rose from 91 to 105 due to inventory buildup; further increases could pressure cash flows.
RISK GONE
Sustained API pricing pressure
API business continues to face pricing softness across key molecules, though the pace of decline has moderated.
RISK GONE
Potential delays in regulatory approvals for new facilities
The injectables facility is still ramping up with low utilization; delays in client audits or approvals could impact revenue contribution.
RISK GONE
Trade generic segment losses may persist
Trade generic revenue declined 18% YoY and remains loss-making; management expects some bottom-line impact in Q4.
RISK GONE
Dependence on CDMO volume growth sustainability
Analyst questioned whether the strong volume growth is sustainable; management cited market share gains but acknowledged it's market-driven.
Fast read
Guidance and risk preview
Management expects continued double-digit volume growth in CDMO for the first half of FY27, with visibility of 45-60 days.
API prices remain lower than last year despite recent uptick; further decline could delay turnaround and keep losses elevated.
View Risks →